Harnessing Bacterial Vectors to Deliver Next-Generation Immunotherapy
Pancreas cancer remains one of the most lethal and treatment-resistant cancers, defying chemotherapy, radiotherapy, and even the latest immunotherapies.
For years, progress was limited — until a breakthrough mRNA vaccine trial in 2024 demonstrated, for the first time, prolonged relapse-free survival through use of selected tumoral antigens triggering effective immune activation.
Engineered Bacteria as Living Immune Vehicles
We aim to replicate and surpass mRNA vaccine efficacy using genetically engineered, tumor-targeting bacteria. This attenuated bacterial strain is used as therapeutic vaccine designed to:
• Selectively colonize the tumor microenvironment
• Deliver tumor-specific neoantigens for potent, localized T-cell activation
• Co-deliver immunostimulants directly within the tumor
• Disrupt cancer-associated fibroblasts (CAFs) to break down fibrotic barriers
Our innovative approach merges two validated technologies: personalized cancer vaccines and tumor-targeting bacterial vectors. The result is a modular, scalable, and cost-effective platform designed to overcome resistance in aggressive solid tumors like pancreatic cancer.
Key advantages of our platform:
We’re now advancing this concept to the next level.